SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation

Levi & Korsinsky announces it has commenced an investigation of Celgene Corporation (“Celgene” or “the Company”) (NASDAQGS:CELG) concerning possible violations of federal securities laws.

On October 19, 2017, Celgene announced that it would discontinue its trials for GED-0301 and would record a $1.6 billion impairment charge because of the drug’s failure. On October 26, 2017, Celgene identified some of its key drugs that had missed sales expectations for the quarter. Then on February 27, 2018, post-market, Celgene disclosed that the U.S. Food and Drug Administration (“FDA”) had rejected the Company’s New Drug Application (“NDA”) for Ozanimod, a multiple sclerosis treatment. Celgene stated that it had received a refusal-to-file letter from the FDA, which advised the Company that it had “determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review. ” To obtain additional information, go to:

http://www.zlkdocs.com/CELG-Info-Request-Form-6576

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005795/en/